Secaucus-Based Quest Diagnostics Fined $13 Million For Alleged Kickback Violations

Quest Diagnostics (DGX) agreed to pay a $13 million fine to settle allegations it violated anti-kickback laws by offering doctors and executives free perks, including Giants tickets, to induce business referrals between 2013 and 2022, according to U.S. prosecutors.

Original reporting
Published Nov 9, 2026, 5:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Secaucus-Based Quest Diagnostics Fined $13 Million For Alleged Kickback Violations — source image
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

The settlement resolves allegations spanning 2013‑2022 and includes a $13 M civil penalty, highlighting compliance risks in the health‑care services industry.

02

Market read

First disclosure of a material enforcement action against a mid‑cap health‑care services firm, introducing compliance risk and modest financial impact.

03

What to watch

Potential for further investigations or additional penalties if other violations are uncovered.

Relevance 6/10Novelty 6/10Timing: today

Background

Quest Diagnostics, a leading U.S. laboratory testing company, was charged with offering illegal kickbacks to physicians and executives via free Giants stadium events, violating the Anti‑Kickback Statute.

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

Quest Diagnostics settled a $13 million anti‑kickback fine, the first public disclosure of the enforcement action.

Expected impact

downward pressure as investors price in the fine and potential future regulatory scrutiny

Evidence & confidence

A $13 M fine is material for a mid‑cap health‑care services firm and signals heightened enforcement risk, which typically depresses the stock.

Market effects

May raise compliance costs and scrutiny for other lab‑testing and health‑care service providers.

Limited to U.S. health‑care services sector; no broader regional effect.

Minimal global impact; primarily a U.S. regulatory matter.

Counterpoint

The fine is relatively small versus Quest's revenue, so the market may overreact; the stock could rebound quickly.

Key entities

  • Quest Diagnostics, Inc.

    U.S. lab‑testing services provider, ticker DGX.

  • U.S. Attorney Robert Frazer

    Announced the settlement on behalf of the Department of Justice.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.